StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Keros Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -572.1%. For fiscal 2025 it was 35.7%, against -101319.2% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202535.7%+101354.9
FY2023Dec 31, 2023-101319.2%−101026.9
FY2021Dec 31, 2021-292.3%−168.9
FY2019Dec 31, 2019-123.4%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 2026-74087.5%−74157.8
Q4 FY2025Dec 31, 2025-6173.9%+21968.0
Q3 FY2025Sep 30, 2025-51.5%+492948.5
Q2 FY2025Jun 30, 2025-169.0%−134.3
Q1 FY2025Mar 31, 202570.3%+15692.3
Q4 FY2023Dec 31, 2023-28142.0%−28031.9
Q3 FY2023Sep 30, 2023-493000.0%−492858.0
Q4 FY2021Dec 31, 2021-34.7%+79.4
Q2 FY2021Jun 30, 2021-15622.0%−15494.7
Q4 FY2019Dec 31, 2019-110.0%–
Q3 FY2019Sep 30, 2019-142.0%–
Q2 FY2019Jun 30, 2019-114.1%–
Q1 FY2019Mar 31, 2019-127.3%–

More Keros Therapeutics figures

See a number that looks wrong?